정규장
Log in Sign up
AKAN
AKAN
Akanda Corp
7월 28일 10:59 AM ET (한국 7/28 23:59)
$6.31
-1.42 ▼ -18.37%

아칸다(AKAN) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$5M
스몰캡
P/E
-
배당수익률
없음
52주 위치
2%
저점 +175% · 고점 -97%
애널리스트
-
D
Fundamental health
vs. 초고성장주 초소형주· based on 2 axes
수익성
산출 불가 (적자)
성장
Top 32%
밸류에이션
데이터 부족
재무 안정
Top 100%
Index -P/E -EPS (ttm) -145.41Insider Own 31.16%Shs Outstand 0.8MPerf Week -28.05%
Market Cap 0.00BForward P/E -EPS next Y -Insider Trans -Shs Float 0.5MPerf Month -57.59%
Enterprise Value 0.02BPEG -EPS next Q -Inst Own 0.83%Short Float 1.16%Perf Quarter -48.41%
Income -0.05BP/S 19.06EPS this Y -Inst Trans -1.57%Short Ratio 0.01Perf Half Y -6.52%
Sales 0.00BP/B -EPS next 5Y -ROA -654.33%Short Interest 0.01MPerf YTD -38.67%
Book/sh -23.86P/C 9.91EPS past 3/5Y 68.73% 31.61%ROE -62.26%52W High -96.98% ($209.02)Perf Year -92.93%
Cash/sh 0.64P/FCF -Sales past 3/5Y -53.82% 162.72%ROIC -3843.99%52W Low 174.95% ($2.30)Perf 3Y -99.82%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 43.01%Gross Margin -382.68%Volatility(W/M) 27.26% 13.04%Perf 5Y -
Dividend TTM -EV/Sales 67.25Sales Y/Y TTM -69.15%Oper. Margin -2022.32%ATR (14) 1.95Perf 10Y -
Dividend Ex-Date -Quick Ratio 0.58EPS Q/Q -78.89%Profit Margin -17896.95%RSI (14) 25.43Recom -
Dividend Gr. 3/5Y -Current Ratio 0.58Sales Q/Q -28.24%SMA20 -37.44% ($10.09)Beta 14.21Target Price -
Payout -Debt/Eq -Earnings -SMA50 -57.39% ($14.81)Rel Volume 0.18Prev Close $7.73
Employees 8LT Debt/Eq -EPS/Sales Surpr. -SMA200 -61.61% ($16.44)Avg Volume(3M) 1.22MPrice $6.31
IPO 2022/3/15Option/Short No/NoTrades 1976Volume 218,188Change -18.37%
Quarterly earnings trend Quarterly earnings data is not yet available — foreign-listed companies (ADRs) only file annual reports with the U.S., and recently listed companies may not have filed their first quarterly report.

📊 Akanda Corp (AKAN) Investment Analysis

What kind of company is Akanda Corp?

아칸다(AKAN) 초고성장주
Healthcare · Drug Manufacturers - Specialty & Generic
Small-Cap — Low Volume, High Volatility

🌿 Akanda () is a micro-cap company that cultivates and distributes medical cannabis while also operating telecommunications infrastructure (cell towers and dark fiber) in Mexico. It supplies medical cannabis grown in Lesotho and Portugal to the medical cannabis markets in the UK and Germany, while expanding its business scope into Mexican cell tower and fiber optic operations through its subsidiary First Towers & Fiber.

Learn more about Akanda Corp →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5667
Employees8people
IPO2022/03/15
Current Price$6.31 ≈ 8,645원
NASD · United Kingdom

Key Events

예정된 이벤트가 없습니다

AKAN의 다음 실적 발표일이나 배당 일정이 아직 수집되지 않았습니다.

  • 실적 발표는 보통 분기마다 있습니다
  • 배당주는 연 1~4회 배당락일이 있습니다
전체 경제/실적 캘린더 보기 →

Is it profitable?

Both profitability & finances need caution
Review management risk carefully before investing
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-2022.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-17897.0%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
-382.7%
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic 초소형주 Median 26.6% · Bottom tier
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-62.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-654.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-3844.0%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Current Ratio
Liquid assets available to cover liabilities due within a year
0.58
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 2.47
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
0.58
✓ 매우 부진
My positionBottom 5%
Low range Average High range
Drug Manufacturers - Specialty & Generic Median 1.68
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Outlook data is insufficient

Analyst estimates and price targets have not been collected.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
Healthy, Balanced Growth EPS and revenue are both growing steadily — a sustainable growth profile
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+68.7%
우수
My positionTop 25%
Low range Average High range
초고성장주 초소형주 Median 27.5% · Top 17%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+31.6%
양호
My positionMid-range
Low range Average High range
초고성장주 초소형주 Median 20.7% · Top 39%
Past 5-Year Revenue
How much revenue grew over the past 5 years
+162.7%
우수
My positionTop 5%
Low range Average High range
초고성장주 초소형주 Median 47.0% · Top tier
⚡ Short-term momentum
QoQ Revenue
Revenue change from the previous quarter (short-term momentum)
-28.2%
평균
My positionMid-range
Low range Average High range
초고성장주 초소형주 Median 3.6% · Bottom 28%
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Underperformed the market by 109%p over the past year
AKAN -92.9% · S&P 500 +16.0%
Excess return vs. market (price-based, ex-dividends)
1-year basis
vs S&P 500
-108.9%p
Significantly behind the market
vs Health Care (XLV)
-112.7%p
Significantly behind the sector average
Rank among peers
1-year return Lowest among peers Based on 36 peers
Current position within 52-week range
Low (-174.9%p) High (-97.0%p)
Current price is 174.9% above the 52-week low and 97.0% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-88.9%
Annualized volatility
359.9%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 136-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🔴
Current diagnosis · 2026-07-27
Downtrend zone

Current price $6.31 below the midline ($10.09). Normal downward flow. Below the Ichimoku cloud (bearish).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🔴
Current diagnosis · 2026-07-27
Bearish momentum holding

MACD -2.201 < Signal -2.112 in negative zone + Hist negative (-0.089). Weakness in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🔵
Current diagnosis · 2026-07-27
Oversold zone — rebound potential

RSI 25.8 (30 or below). Selling pressure is excessive; a short-term rebound may be worth considering. Stoch %K is also 9.0.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Pricier than peers in its industry
Pricey on Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🧾 Vs. Sales Pricey
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
19.06x
✓ Pricey
My positionBottom 25%
Low range Average High range
Drug Manufacturers - Specialty & Generic 초소형주 median 1.82x · Bottom 19% — expensive within the industry
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Drug Manufacturers - Specialty & Generic 초소형주

Who owns it?

Ownership flow shows some pressure
Institutional net selling -1.6% · Short interest light 1.2%
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
-1.6%
Institutions net selling
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 0.8%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 31.2%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 68.0%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
1.2%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 76 days Little change
Short interest days to cover
0.0 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 0.8M주
Float (tradable shares) 0.5M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 76 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
AKAN AKAN This Stock
$5.0M- - -62.26% - -18.4%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 아칸다(AKAN)?

아칸다(AKAN) belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.

What is the market cap of AKAN?

The market cap of AKAN is approximately $5M, ranking 5,667 within its sector.

What is the 52-week high and low for AKAN?

AKAN has recorded a 52-week high of $209.02 and a low of $2.30.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.